Development of Potential Inhibitors for Human T-lymphotropic Virus Type I Integrase Enzyme : A Molecular Modeling Approach
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
INTRODUCTION: Integration of viral DNA into the host cell genome, carried out by the HTLV-1 integrase enzyme, is a crucial step in the Human T-lymphotropic Virus type I (HTLV-1) life cycle. Thus, HTLV-1 integrase is considered an attractive therapeutic target; however, no clinically effective inhibitors are available to treat HTLV-1 infection.
OBJECTIVE: The main objective was to identify potential drug-like compounds capable of effectively inhibiting HTLV-1 integrase activity.
METHODS: In this study, a model of HTLV-1 integrase structure and three integrase inhibitors (dolutegravir, raltegravir, and elvitegravir as scaffolds) were used for designing new inhibitors. Designed molecules were used as templates for virtual screening to retrieve new inhibitors from PubChem, ZINC15, and ChEMBL databases. Drug-likeness and docked energy of the molecules were investigated using the SWISS-ADME portal and GOLD software. Stability and binding energy of the complexes were further investigated using molecular dynamic (MD) simulation.
RESULTS: Four novel potential inhibitors were developed using a structure-based design protocol and three compounds from virtual screening. They formed hydrogen bonding interactions with critical residues Asp69, Asp12, Tyr96, Tyr143, Gln146, Ile13, and Glu105. In addition, π stacking, halogen, and hydrogen bond interactions were seen between compounds (especially halogenated benzyl moieties) and viral DNA similar to those seen in parent molecules. MD simulation confirmed higher stability of the receptor-ligand complex than the ligand-free enzyme.
CONCLUSION: Combing structure-based design and virtual screening resulted in identifying three drug-like molecules (PubChem CID_138739497, _70381610, and _140084032) that are suggested as lead compounds for developing effective drugs targeting HTLV-1 integrase enzyme.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Current computer-aided drug design - 20(2023), 1 vom: 12., Seite 72-86 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jalili-Nik, Mohammad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
HTLV-1 |
|---|
| Anmerkungen: |
Date Revised 13.10.2023 published: Print Citation Status Publisher |
|---|
| doi: |
10.2174/1573409919666230419082839 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356183548 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356183548 | ||
| 003 | DE-627 | ||
| 005 | 20231226065924.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1573409919666230419082839 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1187.xml |
| 035 | |a (DE-627)NLM356183548 | ||
| 035 | |a (NLM)37114780 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jalili-Nik, Mohammad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of Potential Inhibitors for Human T-lymphotropic Virus Type I Integrase Enzyme |b A Molecular Modeling Approach |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a INTRODUCTION: Integration of viral DNA into the host cell genome, carried out by the HTLV-1 integrase enzyme, is a crucial step in the Human T-lymphotropic Virus type I (HTLV-1) life cycle. Thus, HTLV-1 integrase is considered an attractive therapeutic target; however, no clinically effective inhibitors are available to treat HTLV-1 infection | ||
| 520 | |a OBJECTIVE: The main objective was to identify potential drug-like compounds capable of effectively inhibiting HTLV-1 integrase activity | ||
| 520 | |a METHODS: In this study, a model of HTLV-1 integrase structure and three integrase inhibitors (dolutegravir, raltegravir, and elvitegravir as scaffolds) were used for designing new inhibitors. Designed molecules were used as templates for virtual screening to retrieve new inhibitors from PubChem, ZINC15, and ChEMBL databases. Drug-likeness and docked energy of the molecules were investigated using the SWISS-ADME portal and GOLD software. Stability and binding energy of the complexes were further investigated using molecular dynamic (MD) simulation | ||
| 520 | |a RESULTS: Four novel potential inhibitors were developed using a structure-based design protocol and three compounds from virtual screening. They formed hydrogen bonding interactions with critical residues Asp69, Asp12, Tyr96, Tyr143, Gln146, Ile13, and Glu105. In addition, π stacking, halogen, and hydrogen bond interactions were seen between compounds (especially halogenated benzyl moieties) and viral DNA similar to those seen in parent molecules. MD simulation confirmed higher stability of the receptor-ligand complex than the ligand-free enzyme | ||
| 520 | |a CONCLUSION: Combing structure-based design and virtual screening resulted in identifying three drug-like molecules (PubChem CID_138739497, _70381610, and _140084032) that are suggested as lead compounds for developing effective drugs targeting HTLV-1 integrase enzyme | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HTLV-1 | |
| 650 | 4 | |a integrase | |
| 650 | 4 | |a integrase inhibitors | |
| 650 | 4 | |a ligand-based design | |
| 650 | 4 | |a structure-based design | |
| 650 | 4 | |a virtual screening | |
| 700 | 1 | |a Soltani, Arash |e verfasserin |4 aut | |
| 700 | 1 | |a Hashemy, Seyed Isaac |e verfasserin |4 aut | |
| 700 | 1 | |a Rafatpanah, Houshang |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaee, Seyed Abdolrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Gorji, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Griffith, Renate |e verfasserin |4 aut | |
| 700 | 1 | |a Mashkani, Baratali |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current computer-aided drug design |d 2008 |g 20(2023), 1 vom: 12., Seite 72-86 |w (DE-627)NLM191691046 |x 1875-6697 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2023 |g number:1 |g day:12 |g pages:72-86 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1573409919666230419082839 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2023 |e 1 |b 12 |h 72-86 | ||